Assessment of Residual Or Resected Disappearing Liver Metastases After Chemotherapy: AROD study

UMIN ID: UMIN000057007

Registered date:15/02/2025

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: Colorectal liver metastasis
• Date of first enrollment: 2022/09/01
• Target sample size: 60
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

• Primary Outcome: The recurrence rate at the site of disappeared liver metastases (DLM) in unresected cases and the pathological tumor residual rate in resected DLM cases.
• Secondary Outcome: Recurrence rate, survival rate, prognostic factors, patterns of recurrence, and trends in serum tumor markers.

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female
• Exclude criteria: 1. Patients under 20 years of age at the time of consent acquisition. 2. Cases where contrast-enhanced CT or MRI was not feasible. 3. Patients deemed unfit for surgery based on their overall condition. 4. Cases with more than 50 liver metastases prior to treatment, as accurately counting them was deemed impractical. 5. Other cases deemed unsuitable as study subjects by the principal investigator.

Related Information

• Primary Sponsor: Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo
• Source(s) of Monetary Support: none